Get the Stockscreener App
3.15
1.61%
0.05
After Hours:
3.18
0.03
+0.95%
Imunon Inc stock is traded at $3.15, with a volume of 54,605.
It is up +1.61% in the last 24 hours and up +5.35% over the past month.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
See More
Previous Close:
$3.10
Open:
$3.05
24h Volume:
54,605
Relative Volume:
0.62
Market Cap:
$12.36M
Revenue:
$125.00K
Net Income/Loss:
$-14.50M
P/E Ratio:
-0.6841
EPS:
-4.6043
Net Cash Flow:
$-14.18M
1W Performance:
+0.64%
1M Performance:
+5.35%
6M Performance:
-34.38%
1Y Performance:
-72.50%
1-Day Range:
$3.0401
$3.19
1-Week Range:
$2.90
$3.21
52-Week Range:
$2.52
$41.22
Imunon Inc Stock (IMNN) Company Profile
Name
Imunon Inc
Sector
Industry
Phone
(609) 896-9100
Address
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
3.15 | 12.16M | 125.00K | -14.50M | -14.18M | -4.6043 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Imunon Inc Stock (IMNN) Latest News
Is Imunon Inc stock a good pick for beginnersWeekly Trade Report & High Return Trade Opportunity Guides - baoquankhu1.vn
Imunon (IMNN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Imunon, Inc. (NASDAQ:IMNN) Q4 2025 Earnings Call Transcript - MSN
Guidance Update: Can Imunon Inc reach all time highs this year2026 Stock Rankings & AI Forecast Swing Trade Picks - baoquankhu1.vn
Institution Moves: Can Imunon Inc sustain earnings growth2026 Outlook & AI Forecasted Stock Moves - baoquankhu1.vn
Investment Review: Can Imunon Inc continue delivering strong returns2026 Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
HC Wainwright Brokers Increase Earnings Estimates for Imunon - Defense World
IMNN Technical Analysis & Stock Price Forecast - Intellectia AI
Imunon Earnings Call: Strong Data, Tight Cash Runway - TipRanks
Imunon Q4 Earnings Call Highlights - Defense World
IMNN PE Ratio & Valuation, Is IMNN Overvalued - Intellectia AI
Imunon, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
IMUNON reports final Phase 2 data for ovarian cancer treatment By Investing.com - Investing.com South Africa
Imunon targets ~80 OVATION 3 patients in the next 12 months as cash runway extends into H2 2026 - MSN
Imunon Inc (IMNN) Q4 2025 Earnings Call Highlights: Strategic Ad - GuruFocus
IMUNON 2025 Financial Review - AlphaStreet
IMUNON Reports 2025 Financial Results and Highlights Breakthrough Phase 3 Progress for IMNN-001 in Advanced Ovarian Cancer - Minichart
Imunon Inc’s 2025 Q4 Earnings Call: FDA Submission Delays, Shifting Trial Timelines, and Enrollment Discrepancies Highlight Contradictions - Bitget
IMUNON INC (NASDAQ:IMNN) Reports Q4 2025 Results with Focus on Phase 3 Progress for IMNN-001 - ChartMill
Earnings call transcript: Imunon Inc’s Q4 2025 shows cost discipline, clinical progress - Investing.com
IMUNON ($IMNN) Releases Q4 2025 Earnings - Quiver Quantitative
IMUNON, INC. 2025 Annual Report: Pipeline, Clinical Trials, Financials & Business Strategy Overview - Minichart
Imunon (NASDAQ: IMNN) posts strong IMNN-001 survival data but flags going concern risk - Stock Titan
Imunon Reports 2025 Financial Results And Provides Business Update - TradingView — Track All Markets
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study - The Manila Times
Imunon reports $14.5M net loss and $8.8M cash at year-end; highlights Phase 3 progress - TradingView — Track All Markets
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
IMUNON (IMNN) highlights 2025 loss reduction and strong IMNN-001 survival data - Stock Titan
IMUNON Reports 2025 Financial Results and Provides Business - GlobeNewswire
Imunon Scheduled to Announce Q4 Earnings on March 30 - Intellectia AI
Inflation Data: Can Imunon Inc sustain earnings growthPortfolio Profit Report & Verified Technical Trade Signals - baoquankhu1.vn
IMUNON reports improved survival data for ovarian cancer therapy By Investing.com - Investing.com South Africa
Imunon Inc. Expands Market Footprint Amid Strategic Deals and Financial Challenges - timothysykes.com
IMUNON's IMNN-001 Shows Continued Gains In Overall Survival In Phase 2 Ovarian Cancer Trial - RTTNews
Imunon (IMNN) Reports Promising Phase 2 OVATION 2 Trial Results - GuruFocus
IMUNON reports improved survival data for ovarian cancer therapy - investing.com
With PARP therapy, women on IMUNON lived 24.2 months longer - stocktitan.net
Aug Closing: Is Imunon Inc stock a good pick for beginners2026 Big Picture & Real-Time Volume Analysis Alerts - baoquankhu1.vn
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 - marketscreener.com
IMUNON, Inc. Files Form 8-K with NASDAQ Listing and Company Details for March 2026 - Minichart
Imunon Expands At-The-Market Equity Offering Capacity - TipRanks
Imunon registers additional $7 million in shares under at-the-market offering - Investing.com India
Imunon registers additional $7M, raising ATM capacity to $17M - TradingView
Imunon (NASDAQ: IMNN) boosts at-the-market stock program to $17M - Stock Titan
Imunon (NASDAQ: IMNN) ups ATM program by $7M to $17M capacity - Stock Titan
S P Trends: What is the next catalyst for Imunon Inc2026 Weekly Recap & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Dividend Watch: Will Imunon Inc outperform tech stocksQuarterly Profit Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Imunon Q2 2025 Earnings Preview - MSN
Imunon declares $0.15 dividend - MSN
Signal Recap: Will Imunon Inc outperform tech stocksGold Moves & Low Risk Entry Point Guides - baoquankhu1.vn
Market Overview: Is Imunon Inc a defensive stock2025 Key Highlights & Smart Swing Trading Techniques - baoquankhu1.vn
Imunon Inc Stock (IMNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):